Biotech News

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant (IMVT)Immunovant2025-12-11 06:29 ESTFinancing

IMVT (IMVT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is imvt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

IMVTImmunovant2026-05-11 20:05 EST

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

IMVTImmunovant2026-04-02 09:00 EST

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

IMVTImmunovant2026-02-06 12:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

IMVTImmunovant2026-01-23 22:25 EST

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

IMVTImmunovant2025-11-10 12:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

IMVTImmunovant2025-10-27 20:10 EST

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMVTImmunovant2025-09-03 16:57 EST

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

IMVTImmunovant2025-08-11 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

View all latest news

Immunovant

Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.

Recent company news

IMVTBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

IMVTQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

IMVTMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

IMVTAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

Stock data

Close: 39.37 USD
Market cap: 6.35B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States